{
    "organizations": [],
    "uuid": "9b56e1fcbe80b9d88285c861f0da18664a06be32",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-teva-announces-fda-approval-of-tri/brief-teva-announces-fda-approval-of-trisenox-to-treat-acute-promyelocytic-leukemia-idUSASB0C0WK",
    "ord_in_thread": 0,
    "title": "BRIEF-Teva Announces FDA Approval Of Trisenox To Treat Acute Promyelocytic Leukemia",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 15 (Reuters) - Teva Pharmaceutical Industries Ltd :\n* TEVA ANNOUNCES U.S. FDA APPROVAL OF TRISENOX® (ARSENIC TRIOXIDE) INJECTION FOR FIRST LINE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA\n* TEVA PHARMACEUTICAL-‍APPROVAL BASED ON REVIEW BY FDA ON DATA FROM PUBLISHED SCIENTIFIC LITERATURE AND CO‘S GLOBAL SAFETY DATABASE FOR ARSENIC TRIOXIDE​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-15T21:24:00.000+02:00",
    "crawled": "2018-01-16T13:12:34.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "teva",
        "pharmaceutical",
        "industry",
        "ltd",
        "teva",
        "announces",
        "fda",
        "approval",
        "arsenic",
        "trioxide",
        "injection",
        "first",
        "line",
        "treatment",
        "acute",
        "promyelocytic",
        "leukemia",
        "teva",
        "based",
        "review",
        "fda",
        "data",
        "published",
        "scientific",
        "literature",
        "co",
        "global",
        "safety",
        "database",
        "arsenic",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}